MBOAT7 and liver disorder: Moreover, the major substrate of MBOAT7, lysophosphatidylinositol, has been proposed to be a crucial mediator for progression of obesity-linked liver disease, as MBOAT7 knockdown in mice treated with lysophosphatidylinositol lipids worsened hepatic inflammatory and fibrotic gene expression [124].